KOD stock icon

Kodiak Sciences

3.84 USD
+0.04
1.05%
At close Nov 1, 4:00 PM EDT
After hours
3.81
-0.03
0.78%
1 day
1.05%
5 days
2.40%
1 month
47.69%
3 months
32.87%
6 months
8.78%
Year to date
20.75%
1 year
149.35%
5 years
-82.55%
 

About: Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is KSI-301, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD.

Employees: 111

0
Funds holding %
of 6,759 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

58% more call options, than puts

Call options by funds: $52K | Put options by funds: $33K

15% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 27

5% less funds holding

Funds holding: 110 [Q1] → 104 (-6) [Q2]

8.95% less ownership

Funds ownership: 85.97% [Q1] → 77.02% (-8.95%) [Q2]

21% less first-time investments, than exits

New positions opened: 22 | Existing positions closed: 28

60% less capital invested

Capital invested by funds: $237M [Q1] → $95.1M (-$142M) [Q2]

100% less funds holding in top 10

Funds holding in top 10: 1 [Q1] → 0 (-1) [Q2]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$3
22%
downside
Avg. target
$3
22%
downside
High target
$3
22%
downside

2 analyst ratings

positive
0%
neutral
100%
negative
0%
HC Wainwright & Co.
Matthew Caufield
33% 1-year accuracy
13 / 39 met price target
22%downside
$3
Neutral
Reiterated
24 Sept 2024
HC Wainwright & Co.
Matthew Caufield
33% 1-year accuracy
13 / 39 met price target
22%downside
$3
Neutral
Initiated
5 Sept 2024

Financial journalist opinion

Charts implemented using Lightweight Charts™